Khiron Life Sciences Corp. (OTCMKTS:KHRNF) is a diversified medical cannabis company focused on the development, cultivation and sale of cannabinoid-based products in Latin America. The company operates a fully integrated value chain encompassing seed genetics, cultivation, extraction, manufacturing and distribution. Through its subsidiaries in Colombia, Khiron produces a range of medical cannabis products including oils, capsules, topicals and various formulations under the Khiron and Moti-Gel brands.
Since its incorporation in 2017, Khiron has pursued a strategy of combining medical expertise with patient-focused care. The company has established a network of medical clinics and telemedicine partnerships across Colombia to facilitate patient access to cannabis-based treatments. Khiron’s team of physicians, pharmacists and agronomists collaborates on real-world evidence studies, monitors patient outcomes and develops treatment protocols for conditions such as chronic pain, anxiety and epilepsy.
Geographically, Khiron maintains a strong presence in Colombia, where it operates a GMP-certified manufacturing facility and multiple cultivation sites with an annual production capacity in the thousands of kilograms of dried flower. The company has also advanced operations in Europe through its Madrid-based subsidiary, targeting markets with established medical cannabis frameworks. Khiron leverages regional regulatory expertise to guide market entry and product registration.
Under the leadership of co-founder and CEO Pablo Grobkovsky, Khiron has pursued strategic partnerships to enhance its product offerings and expand research initiatives. The company’s multidisciplinary scientific team conducts pharmacological research to identify new therapeutic applications for cannabinoids while ensuring compliance with evolving regulatory standards. Khiron’s vertically integrated platform and emphasis on patient education underpin its commitment to delivering quality medical cannabis solutions.
AI Generated. May Contain Errors.